Does Keloid Scarring Receive Similar Federal Support and National Focus as Other Chronic Cutaneous Conditions?

1. Elsaie ML . Update on management of keloid and hypertrophic scars: A systemic review. J Cosmet Dermatol. 2021;20(9):2729–2738; doi: 10.1111/jocd.14310

2. Davis SA , Feldman SR , McMichael AJ . Management of keloids in the United States, 1990-2009: An analysis of the National Ambulatory Medical Care Survey. Dermatol Surg. 2013;39(7):988–994; doi: 10.1111/dsu.12182

3. Huang C , Wu Z , Du Y , et al. The Epidemiology of Keloids. In: Téot L , Mustoe TA , Middelkoop E , Gauglitz GG , eds. Textbook on Scar Management: State of the Art Management and Emerging Technologies. Cham (CH): Springer; 2020.29–35.

4. Olopoenia A , Yamaguchi Y , Peeva E , et al. Demographics, clinical characteristics, and treatment patterns among keloid patients: United States Electronic Health Records (EHR) Database Study. Int J Dermatol. 2024;63(8):e163–e170; doi: 10.1111/ijd.17099

5. Gether L , Overgaard LK , Egeberg A , et al. Incidence and prevalence of rosacea: A systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282–289; doi: 10.1111/bjd.16481

6.“Hidradenitis Suppurativa: Medlineplus Genetics.” MedlinePlus, U.S. National Library of Medicine, medlineplus.gov/genetics/condition/hidradenitis-suppurativa/#frequency [Last accessed: November 6, 2024].